These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18067016)

  • 41. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
    Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association.
    Kridel R; Xerri L; Gelas-Dore B; Tan K; Feugier P; Vawda A; Canioni D; Farinha P; Boussetta S; Moccia AA; Brice P; Chavez EA; Kyle AH; Scott DW; Sanders AD; Fabiani B; Slack GW; Minchinton AI; Haioun C; Connors JM; Sehn LH; Steidl C; Gascoyne RD; Salles G
    Clin Cancer Res; 2015 Aug; 21(15):3428-35. PubMed ID: 25869385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
    Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
    Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.
    Carreras J; Lopez-Guillermo A; Roncador G; Villamor N; Colomo L; Martinez A; Hamoudi R; Howat WJ; Montserrat E; Campo E
    J Clin Oncol; 2009 Mar; 27(9):1470-6. PubMed ID: 19224853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival.
    Chao C; Xu L; Silverberg MJ; Martínez-Maza O; Chen LH; Castor B; Abrams DI; Zha HD; Haque R; Said J
    AIDS; 2015 Sep; 29(15):1943-51. PubMed ID: 26355571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
    Južnič Šetina T; Borštnar S; Jezeršek Novaković B
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
    Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
    Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival.
    Tumedei MM; Piccinini F; Azzali I; Pirini F; Bravaccini S; De Matteis S; Agostinelli C; Castellani G; Zanoni M; Cortesi M; Vergani B; Leone BE; Righi S; Gazzola A; Casadei B; Gentilini D; Calzari L; Limarzi F; Sabattini E; Pession A; Tazzari M; Bertuzzi C
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Follicular lymphoma: 2011 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2011 Sep; 86(9):768-75. PubMed ID: 21850659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma.
    Alvaro T; Lejeune M; Camacho FI; Salvadó MT; Sánchez L; García JF; Lopez C; Jaén J; Bosch R; Pons LE; Bellas C; Piris MA
    Haematologica; 2006 Dec; 91(12):1605-12. PubMed ID: 17145596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
    Sacchi S; Pozzi S; Marcheselli L; Bari A; Luminari S; Angrilli F; Merli F; Vallisa D; Baldini L; Brugiatelli M;
    Cancer; 2007 May; 109(10):2077-82. PubMed ID: 17394190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
    Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K
    Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical Features, Treatment and Prognostic Factors of 94 Patients with Follicular Lymphoma].
    DU XY; Hu K; Zhao W; Yang P; Wan W; Jing HM; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):756-764. PubMed ID: 29950216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study.
    Johnston A; Bouafia-Sauvy F; Broussais-Guillaumot F; Michallet AS; Traullé C; Salles G; Coiffier B
    Leuk Lymphoma; 2010 Mar; 51(3):399-405. PubMed ID: 20038227
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.
    Cicone F; Russo E; Carpaneto A; Prior JO; Delaloye AB; Scopinaro F; Ketterer N
    Hematol Oncol; 2011 Sep; 29(3):131-8. PubMed ID: 20862654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
    Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
    J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intralesional rituximab for the treatment of localised palatal relapse of follicular lymphoma.
    Peinert S; Kamel S; Seymour JF; Prince HM
    Leuk Lymphoma; 2009 Feb; 50(2):303-5. PubMed ID: 19197721
    [No Abstract]   [Full Text] [Related]  

  • 60. Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance.
    Kusano Y; Yokoyama M; Inoue N; Yamauchi H; Takahashi A; Tsuyama N; Mishima Y; Nishimura N; Takeuchi K; Terui Y; Hatake K
    Ann Hematol; 2018 Feb; 97(2):289-297. PubMed ID: 29138885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.